Valuation: Autolus Therapeutics plc

Market Cap 242M 220M 203M 184M 346M 22.38B 364M 2.47B 981M 12.22B 907M 888M 38.36B P/E 2026 *
-1.13x
P/E 2027 * -1.43x
Enterprise Value 152M 138M 127M 116M 217M 14.05B 228M 1.55B 616M 7.68B 569M 557M 24.09B EV / Sales 2026 *
1x
EV / Sales 2027 * 1.26x
Free-Float
99%
Yield 2026 *
-
Yield 2027 * -
1 day-7.38%
1 week-22.45%
Current month-40.31%
1 month-43.99%
3 months-62.35%
6 months-45.01%
Current year-54.41%
1 week 0.9
Extreme 0.8963
1.17
1 month 0.9
Extreme 0.8963
1.65
Current year 0.9
Extreme 0.8963
2.58
1 year 0.9
Extreme 0.8963
2.58
3 years 0.9
Extreme 0.8963
7.45
5 years 0.9
Extreme 0.8963
7.45
10 years 0.9
Extreme 0.8963
53.24
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 01/09/2014
Chief Executive Officer 61 01/03/2016
Director of Finance/CFO 56 07/08/2023
Director TitleAgeSince
Chairman 61 01/10/2014
Director/Board Member 78 01/08/2014
Director/Board Member 71 01/03/2018
Date Insider Type Main position Quantity % Market Cap. Importance
2/9/26 Sell

Executive/Senior Manager

-6,713 0.0025%
29/6/26 Free

Director

79,167 0.0477%
18/3/26 Other

Chief Executive Officer

6,917,877 4.1641%
Change 5-day change 1-year change 3-year change Capi.($)
-7.38%-22.45%-26.24%-77.60% 242M
-0.30%-6.68%+27.12%+127.32% 1,200B
+1.25%-5.35%+32.65%+78.98% 651B
+0.94%-2.99%+21.13%+106.30% 506B
-0.60%-1.95%+25.73%+67.00% 377B
+0.69%-9.50%+36.78%+30.83% 330B
+0.41%-4.70%+24.18%+50.18% 288B
+0.81%-4.08%-2.95%+31.59% 272B
-0.15%-6.45%+29.06%+65.76% 236B
-0.06%-0.98%+31.42%+122.83% 206B
Average -0.44%-6.52%+19.89%+60.32% 407B
Weighted average by Cap. +0.30%-5.19%+26.02%+87.87%

Financials

2026 *2027 *
Net sales 152M 139M 128M 116M 218M 14.11B 229M 1.56B 618M 7.7B 572M 560M 24.18B 197M 179M 165M 150M 282M 18.23B 296M 2.01B 799M 9.96B 739M 723M 31.25B
Net income -213M -194M -179M -163M -305M -19.75B -321M -2.18B -866M -10.79B -800M -783M -33.85B -172M -157M -144M -131M -246M -15.93B -259M -1.76B -699M -8.7B -646M -632M -27.32B
Net Debt -89.88M -81.86M -75.43M -68.61M -129M -8.32B -135M -918M -365M -4.55B -337M -330M -14.27B 5.67M 5.17M 4.76M 4.33M 8.12M 525M 8.54M 57.93M 23.02M 287M 21.28M 20.83M 900M
Projected Income Statement - Annual - Autolus Therapeutics plc
Logo Autolus Therapeutics plc
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Employees
753
Date Price Change Volume
20/11/26 US$0.9073 -7.38% 3,898,442
19/11/26 US$0.9796 -7.58% 5,247,738
18/11/26 US$1.060 -2.75% 2,559,887
17/11/26 US$1.090 -4.39% 2,178,004
16/11/26 US$1.140 -2.56% 2,351,701
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Autolus Therapeutics plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
0.9073USD
Average target price
8.362USD
Spread / Average Target
+821.69%
  1. Stock Market
  2. Stocks
  3. AUTL Stock